DOBUTAMINE IN THE MANAGEMENT OF DECOMPENSATED HEART FAILURE: EVIDENCE AND CLINICAL IMPLICATIONS FROM A LITERATURE REVIEW

Abstract

Decompensated heart failure represents a clinical condition with high morbidity and mortality, often associated with reduced cardiac output and tissue hypoperfusion, requiring rapid therapeutic interventions to achieve hemodynamic stabilization. In this context, the use of inotropic agents such as dobutamine plays an important role in the management of patients with cardiovascular instability. This study aims to analyze, through a literature review, the main hemodynamic effects of dobutamine in the treatment of decompensated heart failure, as well as to discuss its clinical indications, therapeutic benefits, and potential limitations. To this end, a bibliographic review was conducted using the PubMed, SciELO, and LILACS databases, considering publications between 2013 and 2024, resulting in the final selection of 13 studies addressing the use of dobutamine in the management of heart failure. The findings indicate that dobutamine significantly improves myocardial contractility and increases cardiac output, contributing to hemodynamic stabilization in patients with acute heart failure. However, the literature also highlights potential limitations associated with prolonged use, including the risk of arrhythmias and increased myocardial oxygen consumption. It can be concluded that dobutamine remains an important therapeutic option in the management of decompensated heart failure, particularly in situations requiring rapid hemodynamic intervention, and its use should be carefully monitored and clinically indicated.